Hyalto Injection (Sodium Hyaluronate)

Adult administration

As sodium hyaluronate, 25 mg is administered intra-articularly into the knee joint or shoulder joint (shoulder joint cavity, subacromial bursa, or biceps tendon sheath) once a week for 5 consecutive weeks. Adjust the frequency of administration appropriately based on symptoms. The administration must be performed under strict aseptic conditions.

This medication should not be used in patients with a known allergy to this medication or any of its components. Since it is administered directly into the joint, it should not be given if there are skin disorders or infections at the injection site. Patients with liver dysfunction or a history of liver disease should use this medication cautiously as it may alter liver function tests. Patients with allergies to avian proteins should also avoid using this medication. Serious allergic reactions such as shock may occur, so patients should be closely monitored after administration. If facial or periocular swelling, rash, urticaria, or itching occur, discontinue use immediately and seek appropriate treatment. Transient pain, swelling, redness, warmth, pressure, or bruising may occur at the injection site; patients should be made aware of this. Nausea, vomiting, fever, or headache may also occasionally occur. In cases of severe arthritis, it is recommended to use this medication after the inflammation has subsided, and to stabilize the injection site afterward. If the medication leaks outside of the joint, pain may occur, so it should be administered directly into the joint space. Patients with rheumatoid arthritis or gout may experience temporary worsening of inflammation, so caution is advised. It is advisable to avoid strenuous exercise or prolonged weight-bearing activities for 48 hours after administration. The simultaneous use of this medication with other intra-articular injectables has not been confirmed for safety and efficacy, so it should not be used together. Pregnant women or women of childbearing potential should use this medication cautiously, as its safety has not been established, and treatment should only be considered when the benefits outweigh the risks. Nursing mothers should avoid breastfeeding while using this medication, as it may be excreted in breast milk. Safety has not been established in children, so it should only be used cautiously when absolutely necessary. Elderly patients should be treated with greater caution due to potential declines in bodily functions. Maintain strict asepsis during injection, and discontinue this medication if symptoms do not improve after three to five administrations. If there is excess joint fluid, it is advisable to aspirate this before injection. Intravenous administration is strictly prohibited, and it is not suitable for use in the eyes. When injecting, select an appropriate needle size due to the high viscosity, and ensure to thoroughly shake the solution in the ampoule before use. When cutting the ampoule, clean it well to prevent foreign substances from entering. Caution should be exercised as mixing with certain disinfectants may result in precipitation. This medication is single-use, and any remaining solution should be discarded after opening.

Serious side effects

• Urticaria
• edema (facial, eyelid, etc.)
• shock

Mild side effects

• Facial flushing
• itching
• pain
• swelling
• redness
• warmth
• localized severe pressure
• petechiae
• nausea
• vomiting

This medication should be stored in a sealed container protected from air exposure, at room temperature between 1°C and 30°C. Proper storage will help maintain the efficacy of the drug and prevent deterioration.

Appearance

A colorless, transparent viscous solution filled in a glass vial sealed with rubber stoppers on both ends (part of a prefilled syringe system).

Package unit

2.5 milliliters × 10 vials